Comparison · NCT01371838-sae
Ceftaroline 600mg vs Ceftriaxone 2g: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ceftaroline 600mg vs Ceftriaxone 2g: serious adverse events. Trial comparisons, record NCT01371838-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01371838-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0787 | 0.0557 | 0.11 | wilson | |
| Risk in group 2 | 0.0757 | 0.0532 | 0.107 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00302 | -0.0355 | 0.0417 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.04 | 0.637 | 1.7 | log | |
| Odds ratio, group 1 over group 2 | 1.04 | 0.613 | 1.77 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Ceftaroline 600mg than on Ceftriaxone 2g | 331 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ceftaroline 600mg | Ceftaroline fosamil was administered in two consecutive 300-mg IV infusions over 30 minutes, every 12 hours (q12h) | 30 | 381 | EG000 |
| Group 2 | Ceftriaxone 2g | Ceftriaxone for Injection is supplied as 1 g/vial (2 vials for a 2 grams dose) and a 2 grams dose infused over 30 (±10) minutes q24h (±2h). | 29 | 383 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- first dose, throughout the treatment period, and up to the TOC visit
Source ClinicalTrials.gov
Trial
- Title
A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
- NCT number
- NCT01371838
- Phases
- PHASE3
- Conditions
- Community-Acquired Bacterial Pneumonia, Lung Infection of Individual Not Recently Hospitalized
- Interventions
- Ceftaroline, Ceftriaxone
- Lead sponsor
- Pfizer
- Results first posted
- 2014-09-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01371838?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01371838-sae